Geographical variation in the penetrance of CDKN2A mutations for melanoma.

BACKGROUND Germline mutations in the CDKN2A gene, which encodes two proteins (p16INK4A and p14ARF), are the most common cause of inherited susceptibility to melanoma. We examined the penetrance of such mutations using data from eight groups from Europe, Australia and the United States that are part of The Melanoma Genetics Consortium. METHODS We analyzed 80 families with documented CDKN2A mutations and multiple cases of cutaneous melanoma. We modeled penetrance for melanoma using a logistic regression model incorporating survival analysis. Hypothesis testing was based on likelihood ratio tests. Covariates included gender, alterations in p14ARF protein, and population melanoma incidence rates. All statistical tests were two-sided. RESULTS The 80 analyzed families contained 402 melanoma patients, 320 of whom were tested for mutations and 291 were mutation carriers. We also tested 713 unaffected family members for mutations and 194 were carriers. Overall, CDKN2A mutation penetrance was estimated to be 0.30 (95% confidence interval (CI) = 0.12 to 0.62) by age 50 years and 0.67 (95% CI = 0.31 to 0.96) by age 80 years. Penetrance was not statistically significantly modified by gender or by whether the CDKN2A mutation altered p14ARF protein. However, there was a statistically significant effect of residing in a location with a high population incidence rate of melanoma (P =.003). By age 50 years CDKN2A mutation penetrance reached 0.13 in Europe, 0.50 in the United States, and 0.32 in Australia; by age 80 years it was 0.58 in Europe, 0.76 in the United States, and 0.91 in Australia. CONCLUSIONS This study, which gives the most informed estimates of CDKN2A mutation penetrance available, indicates that the penetrance varies with melanoma population incidence rates. Thus, the same factors that affect population incidence of melanoma may also mediate CDKN2A penetrance.

[1]  D. Housman,et al.  Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s). , 1993, American journal of human genetics.

[2]  J. Hansson,et al.  Melanoma development in relation to non-functional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds. , 1999, Melanoma research.

[3]  G. Mann,et al.  Differential expression of p16INK4a and p16β transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations , 1997, Oncogene.

[4]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[5]  L. Sandkuijl,et al.  Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds , 1995, Nature Genetics.

[6]  Dracopoli Nc,et al.  CDKN2 mutations in melanoma. , 1996 .

[7]  J. Struewing,et al.  Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. , 2000, Journal of the National Cancer Institute.

[8]  N. Gruis,et al.  The Dutch FAMMM family material: clinical and genetic data. , 1992, Cytogenetics and cell genetics.

[9]  Å. Borg,et al.  Novel germline p16 mutation in familial malignant melanoma in southern Sweden. , 1996, Cancer research.

[10]  D. Bishop,et al.  Mutation testing in melanoma families: INK4A, CDK4 and INK4D , 1999, British Journal of Cancer.

[11]  A. Goldstein,et al.  Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect , 2001, Genes, chromosomes & cancer.

[12]  J. Kirkwood,et al.  Homozygous deletions within human chromosome band 9p21 in melanoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Bulliard,et al.  Trends by anatomic site in the incidence of cutaneous malignant melanoma in Canada, 1969–93 , 1999, Cancer Causes & Control.

[14]  W. Kimberling,et al.  Familial atypical multiple mole-melanoma (FAMMM) syndrome: segregation analysis. , 1983, Journal of medical genetics.

[15]  S. Antonarakis.  Recommendations for a nomenclature system for human gene mutations , 1998 .

[16]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[17]  N. Hayward.  The current situation with regard to human melanoma and genetic inferences. , 1996, Current opinion in oncology.

[18]  P. Pollock,et al.  Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds , 1997, Oncogene.

[19]  N. Hayward,et al.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.

[20]  J. Hansson,et al.  Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: A clinic‐based population study , 1998 .

[21]  William D. Foulkes,et al.  The CDKN2A (p16) Gene and Human Cancer , 1997, Molecular medicine.

[22]  L. Dennis,et al.  Recent cohort trends in malignant melanoma by anatomic site in the United States , 1993, Cancer Causes & Control.

[23]  M. Tucker,et al.  The Danish case‐control study of cutaneous malignant melanoma. I. Importance of host factors , 1988, International journal of cancer.

[24]  G. Peters,et al.  Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information , 1999, Oncogene.

[25]  B. Peters,et al.  Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. , 1995, Oncogene.

[26]  J. Struewing,et al.  A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. , 2000, American journal of human genetics.

[27]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[28]  J. A. Bishop,et al.  Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. , 2000, The Journal of investigative dermatology.

[29]  R C Elston,et al.  Lods, wrods, and mods: The interpretation of lod scores calculated under different models , 1994, Genetic epidemiology.

[30]  P. Bruzzi,et al.  Characterization of ligurian melanoma families and risk of occurrence of other neoplasia , 1999, International journal of cancer.

[31]  G. Mann,et al.  CDKN2A (P16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas , 1999, Genes, chromosomes & cancer.

[32]  J M Lalouel,et al.  Combined linkage and segregation analysis using regressive models. , 1988, American journal of human genetics.

[33]  W. Bergman,et al.  Clinical and genetic studies in six Dutch kindreds with the Dysplastic Naevus Syndrome , 1986, Annals of human genetics.

[34]  G. Bonney,et al.  Regressive logistic models for familial disease and other binary traits. , 1986, Biometrics.

[35]  M. Tucker,et al.  Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Skolnick,et al.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.

[37]  M. Inganäs,et al.  Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. , 1997, Journal of the National Cancer Institute.

[38]  A Halpern,et al.  Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. , 1997, JAMA.

[39]  R. DePinho,et al.  Inhibition of ras-induced proliferation and cellular transformation by p16INK4 , 1995, Science.

[40]  A. Houghton,et al.  Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma. , 1987, Cancer research.

[41]  J. Elwood,et al.  Malignant melanoma in England: risks associated with naevi, freckles, social class, hair colour, and sunburn. , 1990, International journal of epidemiology.

[42]  D. Bishop,et al.  Mutation screening of the CDKN2A promoter in melanoma families , 2000, Genes, chromosomes & cancer.

[43]  D. Duffy,et al.  CDKN2A variants in a population-based sample of Queensland families with melanoma. , 1999, Journal of the National Cancer Institute.

[44]  J. Weber,et al.  Confirmation of chromosome 9p linkage in familial melanoma. , 1993, American journal of human genetics.

[45]  W. Clark,et al.  Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. , 1978, Archives of dermatology.

[46]  N. Hayward,et al.  Germline CDKN2A mutations in childhood melanoma. , 1997, Journal of the National Cancer Institute.

[47]  N. Hayward,et al.  Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. , 1995, Human molecular genetics.

[48]  D. Stoppa-Lyonnet,et al.  Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. , 1998, Human molecular genetics.

[49]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[50]  D. Rao,et al.  A time‐dependent logistic hazard function for modeling variable age of onset in analysis of familial diseases , 1990, Genetic epidemiology.

[51]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[52]  U. Francke,et al.  Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. , 1988, Journal of the National Cancer Institute.